marijuana stocks news

Cara Therapeutics to Announce Second Quarter 2016 Financial Results on August 4, 2016

Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2016, at 4:30 p.m. ET to report second quarter 2016 financial results and provide a corporate update.

To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 50082596. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$MDBX Enters Business Agreement to Create Large U.S. Source of CBD Oil

Medbox Enters Business Agreement to Create Large U.S. Source of CBD Oil…

Trulieve Cannabis Corp. (TCNNF) Brings Medical Cannabis to Crystal River

Trulieve Brings Medical Cannabis to Crystal River Trulieve Cannabis Corp. (CSE: TRUL)…

$SING Was Recently The Subject of a MicroCap Equity Research Report

MicroCap Equity Research Covers SinglePoint, Inc. (SING) SinglePoint, Inc. (OTC PINK: SING)…

GT Biopharma Inc. (GTBP) Announces 50% Enrollment in Proof-Of-Concept Clinical Trial For Its Novel Treatment For Motion Sickness

GT Biopharma Inc. (GTBP) (Euronext Paris: GTBP.PA) announced today that the Proof-of-Concept…